ArticleProstate cancer and prostatic diseases2019
Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis.
Article in Prostate cancer and prostatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Survival of Individuals Diagnosed With High-Risk, Regional, and Metastatic Prostate Cancer by Culturally and Linguistically Diverse Status: A Retrospective Cohort Study Set in Victoria, Australia.Cancer medicine · 2026Article
- A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection.British journal of cancer · 2026Article
- The effect of cultural and linguistic diversity on the timeliness of prostate cancer treatment: a registry-based retrospective cohort study.Cancer causes & control : CCC · 2025Article
- Patterns of Care and Treatment Outcomes Among Men Diagnosed with Prostate Cancer from Culturally and Linguistically Diverse Backgrounds: A Scoping Review.Current oncology reports · 2025Article
- Cancer Incidence in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)-The Onco-SOL Ancillary Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.Cancer medicine · 2024Article
- Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men.Prostate cancer and prostatic diseases · 2023Article
- Vitamin D and genetic ancestry are associated with apoptosis rates in benign and malignant prostatic epithelium.The Prostate · 2023Article
- Disparities in germline testing among racial minorities with prostate cancer.Prostate cancer and prostatic diseases · 2022Review
- Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.World journal of urology · 2021Article
- Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort.Prostate cancer and prostatic diseases · 2021Article
- Regional variation in COVID-19 disparities: connections with immigrant and Latinx communities in U.S. counties.Annals of epidemiology · 2021Article
- Helping Men Find Their Way: Improving Prostate Cancer Clinic Attendance via Patient Navigation.Journal of community health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought to evaluate prostate cancer (PCa) characteristics and outcomes of Hispanics living in the United States by country of origin in the Surveillance, Epidemiology and End Results (SEER) program.
methodsRetrospective analysis of 72,134 adult Hispanics with PCa between 1995 and 2014. Origin was Mexican (N = 16,995; 24%), South/Central American (N = 6949; 10%), Puerto Rican (N = 3582; 5%), Cuban (N = 2587; 4%), Dominican (N = 725; 1%), Hispanic not specified (NOS, N = 41,296; 57%), as coded by SEER. Patient and PCa characteristics were analyzed with chi-square and Kruskal-Wallis tests. Overall and PCa survival were analyzed with Kaplan-Meier and Cox models adjusting for baseline variables.
resultsAt diagnosis, Mexicans had more advanced stage, higher prostate-specific antigen, and higher Gleason score while Cubans and Dominicans had more favorable PCa at diagnosis (all P < 0.05). After a median follow-up of 69 months, 20,317 men died, including 6223 PCa deaths. Compared to Mexicans, Cubans (HR = 1.22, 95% CI = [1.14-1.30]) and Puerto Ricans (HR = 1.15 [1.08-1.22]) had worse overall survival while Dominicans (HR = 0.76 [0.64-0.91]), South/Central Americans (HR = 0.68 [0.65-0.72]), and NOS (HR = 0.81 [0.78-0.84]) had better overall survival. Compared to Mexicans, Cubans (HR = 1.08 [0.96-1.22]) and Puerto Ricans (HR = 1.03 [0.92-1.15]) had similar PCa survival while Dominicans (HR = 0.72 [0.53-0.98]), South/Central Americans (HR = 0.67 [0.60-0.74]), and NOS (HR = 0.68 [0.64-0.73]) had significantly better PCa survival.
conclusionsAmong Hispanics in the United States, disparities in PCa characteristics and survival by country of origin exist, with Dominicans, South/Central Americans, and Hispanic NOS having better PCa survival compared to Mexicans, Cubans, and Puerto Ricans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.